Page last updated: 2024-08-22

vidarabine and Agammaglobulinemia

vidarabine has been researched along with Agammaglobulinemia in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hoshino, A; Ikegame, K; Imai, K; Inoue, T; Kaida, K; Kanegane, H; Morio, T; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Yamashita, M1
Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; LeprĂȘtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L1
Ariga, T; Hershfield, MS; Imai, K; Kanegane, H; Miyawaki, T; Nomura, K; Santisteban, I; Taneichi, H; Wada, T; Yachie, A1
Cabanillas, F; Liboy, I; Pavia, O; Rivera, E1
Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U1
Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C1
Alexandrescu, DT; Wiernik, PH1
Anolik, J; Conners, C; Fisher, RI; Friedberg, JW; Kleiner, A; Rich, L; Walker, AR1

Reviews

2 review(s) available for vidarabine and Agammaglobulinemia

ArticleYear
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2012
[Chronic lymphoid leukemia and intravenous immunoglobulins].
    La Revue de medecine interne, 2007, Volume: 28 Spec No 2

    Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine

2007

Other Studies

6 other study(ies) available for vidarabine and Agammaglobulinemia

ArticleYear
Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
    Journal of hematology & oncology, 2016, Feb-13, Volume: 9

    Topics: Adult; Agammaglobulinemia; Antilymphocyte Serum; Cyclophosphamide; Genetic Diseases, X-Linked; Humans; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2016
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
    Pediatric transplantation, 2013, Volume: 17, Issue:1

    Topics: Adenosine Deaminase; Agammaglobulinemia; Bone Marrow Transplantation; Busulfan; Child, Preschool; Humans; Living Donors; Male; Severe Combined Immunodeficiency; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bacterial Infections; Causality; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine

2006
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
    Haematologica, 2007, Volume: 92, Issue:1

    Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine

2007
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:3

    Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine

2008
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
    Cancer investigation, 2008, Volume: 26, Issue:4

    Topics: Adult; Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; CD4 Lymphocyte Count; Cyclophosphamide; Female; Humans; Immunocompromised Host; Immunoglobulin Class Switching; Immunoglobulins, Intravenous; Immunologic Memory; Immunophenotyping; Lymphoma, Follicular; Rituximab; Sinusitis; Vidarabine

2008